Clinical trial No longer in our active list Phase 3 Interventional Ages 18 and up

Investigating how ziltivekimab affects heart failure and inflammation

Official title: Effects of Ziltivekimab Versus Placebo on Heart Failure Symptoms and Physical Function in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation

Run by Novo Nordisk A/S · NCT06200207 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study is testing a new medication called ziltivekimab to see if it can help people with heart failure and inflammation feel better compared to a placebo.

More Heart Failure trials Research outlook What's coming for Heart failure: the next 6 months to 5 years

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment680 (estimated)
SponsorNovo Nordisk A/S
Industry-sponsored
Drugs / interventionsziltivekimab
Locations240 sites (Alexander City, Alabama and 239 other locations)
Trial IDNCT06200207 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include individuals diagnosed with heart failure (NYHA Class II-III) and elevated levels of inflammation markers.

Probably not a fit

Patients with heart failure who do not meet the specific inclusion criteria or have other significant health issues may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the efficacy of ziltivekimab, a new medication, in treating participants with heart failure and systemic inflammation. Participants will be randomly assigned to receive either ziltivekimab or a placebo, allowing researchers to compare the effects of the active drug against an inactive substance. The study is designed to last for up to 1 year and 4 months, focusing on specific cardiovascular biomarkers to determine eligibility. Ziltivekimab is not yet approved for use, making this trial crucial for understanding its potential benefits.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for patients suffering from heart failure and inflammation.

How similar studies have gone: While ziltivekimab is a novel approach, similar studies targeting inflammation in heart failure have shown promise, indicating potential for success.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Serum high-sensitivity C-reactive protein (hs-CRP) greater than or equal to 2 milligrams per liter (mg/L) at screening (visit 1)
* Disease specific - cardiovascular:
* N-terminal-pro-brain natriuretic peptide (NT-proBNP) greater than or equal to 225 picograms per milliliter (pg/mL) (375 pg/mL for participants with atrial fibrillation/flutter) at screening
* Diagnosis of heart failure (New York heart association (NYHA) Class II-III)
* Left ventricular ejection fraction (LVEF) greater than 40 percent documented by echocardiography within 12 months prior to or at screening (visit 1). The LVEF must be documented in medical records and the most recent measurement must be used to determine eligibility with no interim event signalling potential deterioration in ejection fraction (example myocardial infarction (MI) or heart failure (HF) hospitalisation)
* Structural heart disease and/or functional heart disease documented by echocardiography within 12 months prior to or at screening (visit 1) showing at least one of the following:

  1. Left atrial (LA) volume index greater than 34 milliliter per square meter (mL/m\^2)
  2. LA diameter greater than or equal to 3.8 centimeter (cm)
  3. LA length greater than or equal to 5.0 cm
  4. LA area greater than or equal to 20 square centimeter (cm\^2)
  5. LA volume greater than or equal to 55 milliliter (mL)
  6. Intraventricular septal thickness greater than or equal to 1.1 cm
  7. Posterior wall thickness greater than or equal to 1.1 cm
  8. LV mass index greater than or equal to 115 gram per square meter (g/m\^2) in men or greater than or equal to 95 g/m\^2 in women

  h) E/e' (mean septal and lateral) greater than or equal to 10 i) e' (mean septal and lateral) less than 9 centimeter per second (cm/s)
* No heart failure hospitalisations or urgent heart failure visits between screening and randomisation
* Able to perform the 6-minute walk test (6MWT) at screening with a minimum distance of 100 metres
* Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score lesser than 80 at screening

Exclusion Criteria:

* Medical conditions - cardiovascular:
* Myocardial infarction, stroke, unstable angina pectoris, transient ischaemic attack, or heart failure hospitalisation within 30 days prior to screening (visit 1)
* Systolic blood pressure greater than or equal to 180 millimeters of mercury (mmHg) at screening (visit 1). If the systolic blood pressure is 160-179 mmHg, the patient should be receiving greater than or equal to 3 antihypertensive drugs
* Heart rate above 110 or below 40 beats per minute as evaluated on the Electrocardiogram (ECG) performed at screening (visit 1)
* Planned coronary, carotid or peripheral artery revascularisation known during the screening period (visit 1)
* Planned cardiac device or atrial flutter/atrial fibrillation ablation procedure known during the screening period (visit 1)
* Major cardiac surgical, non-cardiac surgical, or major endoscopic procedure (thoracoscopic or laparoscopic) within the past 60 days prior to randomisation (visit 2) or any major surgical procedure planned at the time of randomisation (visit 2)
* Heart failure due to infiltrative cardiomyopathy (e.g., sarcoid, amyloid), arrhythmogenic right ventricular cardiomyopathy, Takutsubo cardiomyopathy, genetic hypertrophic cardiomyopathy or obstructive cardiomyopathy, active myocarditis, constrictive pericarditis, cardiac tamponade, uncorrected more than moderate primary valve disease
* Primary pulmonary hypertension, chronic pulmonary embolism, severe pulmonary disease including chronic obstructive pulmonary disease (COPD)
* Any other condition judged by the investigator that could account for heart failure symptoms and signs (e.g., anaemia, hypothyroidism)
* Medical conditions - infections/immunosuppression:
* Clinical evidence of, or suspicion of, active infection at the discretion of the investigator

Where it's running

  • Valley Clinical Trials, Inc.
    Northridge, California, United States
    Recruiting
  • Clearwater Cardiovascular Consultants
    Largo, Florida, United States
    Recruiting
  • Kansas City VA Medical Center
    Kansas City, Missouri, United States
    Recruiting
  • PharmaTex Research
    Amarillo, Texas, United States
    Recruiting
  • Centro Médico CIMEL
    Lanús Este, Buenos Aires, Argentina
    Recruiting
  • CIPREC Pueyrredon
    Buenos Aires, Argentina
    Recruiting
Show 44 more locations
  • Centro Cardiovascular Salta
    Salta, Argentina
    Recruiting
  • John Hunter Hospital
    New Lambton Heights, New South Wales, Australia
    Recruiting
  • The Prince Charles Hospital
    Brisbane, Queensland, Australia
    Recruiting
  • Diabetes Heart Research Centre
    Toronto, Ontario, Canada
    Recruiting
  • CPS Research
    Waterloo, Ontario, Canada
    Recruiting
  • St John's Medical College Hospital
    Bengaluru, Karnataka, India
    Recruiting
  • Sengupta Hospital and Research Institute
    Nagpur, Maharashtra, India
    Recruiting
  • All India Institute of Medical Sciences (AIIMS), Bhubaneswar
    Bhubaneswar, Odisha, India
    Recruiting
  • Hospital Sultanah Aminah
    Johor Bahru, Johor, Malaysia
    Recruiting
  • University Malaya Medical Centre
    Kuala Lumpur, Kuala Lumpur, Malaysia
    Recruiting
  • Hospital Raja Perempuan Zainab II
    Kota Bharu, Kelantan, Malaysia
    Recruiting
  • Trialmed Sp. z o. o.
    Piotrkow Trybunalski, Poland
    Recruiting
  • Erciyes Üniversitesi Hastanesi- Kardiyoloji
    Kayseri, Turkey (Türkiye)
    Recruiting
  • Advanced Cardiovascular, LLC
    Alexander City, Alabama, United States
    Completed
  • Eastern Shore Rsrch Inst, LLC
    Fairhope, Alabama, United States
    Active not recruiting
  • Cardiology & Medicine Clinic
    Little Rock, Arkansas, United States
    Completed
  • Valley Clinical Trials, Inc.
    Northridge, California, United States
    Active not recruiting
  • UCI Health
    Orange, California, United States
    Completed
  • South California Heart Spc
    Pasadena, California, United States
    Active not recruiting
  • Clearwater Cardiovascular Consultants
    Largo, Florida, United States
    Completed
  • Ocala Cardiovascular Research
    Ocala, Florida, United States
    Active not recruiting
  • Ormond Beach Clinical Research
    Ormond Beach, Florida, United States
    Active not recruiting
  • St Johns Ctr Clin Rsch-St. Aug
    Saint Augustine, Florida, United States
    Active not recruiting
  • GA Arrhythmia Cons & Rsch Inst
    Macon, Georgia, United States
    Active not recruiting
  • Velocity Clin Rsrch - Savannah
    Savannah, Georgia, United States
    Completed
  • Chicago Medical Research LLC
    Hazel Crest, Illinois, United States
    Completed
  • UofL Health Care Outpatient
    Louisville, Kentucky, United States
    Active not recruiting
  • Maryland Cardiovascular Specialists - Baltimore
    Baltimore, Maryland, United States
    Completed
  • MD Medical Research
    Oxon Hill, Maryland, United States
    Completed
  • Cardio and Vascular Assoc-CAVA
    Bloomfield Hills, Michigan, United States
    Active not recruiting
  • Millennium Cardiology
    Farmington Hills, Michigan, United States
    Active not recruiting
  • Kansas City VA Medical Center
    Kansas City, Missouri, United States
    Completed
  • Washington University
    St Louis, Missouri, United States
    Active not recruiting
  • Renown Regional Medical Center
    Reno, Nevada, United States
    Active not recruiting
  • Long Island Cardiovascular Consultants PC
    Lake Success, New York, United States
    Completed
  • Mount Sinai Hosp at NYC
    New York, New York, United States
    Active not recruiting
  • Northwell Health Phys Cardio
    Riverhead, New York, United States
    Active not recruiting
  • University Of North Carolina At Chapel Hill
    Chapel Hill, North Carolina, United States
    Active not recruiting
  • AMS Cardiology
    Horsham, Pennsylvania, United States
    Active not recruiting
  • Univ of Pennsylvania Hospital
    Philadelphia, Pennsylvania, United States
    Active not recruiting
  • PharmaTex Research
    Amarillo, Texas, United States
    Active not recruiting
  • University of Texas Southwestern Medical Center
    Dallas, Texas, United States
    Active not recruiting
  • David Turbay, MD, PLLC
    El Paso, Texas, United States
    Active not recruiting
  • Private Practice Leadership LLC.
    Katy, Texas, United States
    Completed

+190 more sites. See ClinicalTrials.gov for the full list.

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.